GOVX
HEALTHCAREGeovax Labs Inc
$1.65+0.23 (+16.20%)PRE
Live · NASDAQ · May 8, Close
AI Insight
What's Moving GOVX Today?
No stock-specific AI insight has been generated for GOVX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.96$34.75
$1.65
Fundamentals
Market Cap$5M
P/E Ratio—
EPS$-22.40
Dividend Yield—
Dividend / Share—
ROE-4.8%
Profit Margin—
Debt / Equity—
Trading
Volume1.4M
Avg Volume (10D)—
Shares Outstanding2.9M
GOVX News
21 articles- GeoVax (Nasdaq: GOVX) raises $595K, adds new warrant packageStock Titan·May 8, 2026
- GeoVax Announces a Warrant Inducement TransactionThe Globe and Mail·May 7, 2026
- GeoVax Initiates Phase 3 Execution Activities for GEO-MVA Under EMA-Aligned Immunobridging PathwayYahoo Finance·May 6, 2026
- GeoVax Advances Gedeptin(R) Toward Phase 2 Initiation and Strategic Partnership OpportunitiesYahoo Finance·Apr 29, 2026
- GeoVax Highlights Gedeptin(R) as a Potential Immune-Sensitizing Platform Amid Rising Industry Investment in In Vivo Cancer TherapiesYahoo Finance·Apr 27, 2026
- GeoVax Reports 2025 Year-End Financial Results and Provides Business UpdateYahoo Finance·Apr 15, 2026
- How The GeoVax Labs (GOVX) Story Is Shifting After The Rating Downgrade And Valuation ResetYahoo Finance·Apr 14, 2026
- GeoVax Positions GEO-MVA to Address Supply Constraints in Global Mpox and Smallpox Vaccine MarketYahoo Finance·Apr 14, 2026
- GeoVax Highlights Single-Dose Mpox Vaccine Data at World Vaccine Congress 2026Yahoo Finance·Apr 2, 2026
- Why The GeoVax Labs (GOVX) Story Is Shifting As Valuation Holds And Risks RiseYahoo Finance·Mar 31, 2026
- GeoVax Provides Update on GEO-MVA ProgramYahoo Finance·Mar 25, 2026
- GeoVax Announces European Society of Medicine Publication Highlighting GEO-CM04S1 as a Next-Generation COVID-19 Vaccine for Immunocompromised PatientsYahoo Finance·Mar 12, 2026
- How The Story On GeoVax Labs (GOVX) Is Shifting Toward Execution Risk And Funding ConstraintsYahoo Finance·Mar 11, 2026
- GeoVax Initiates Outreach Regarding Future Procurement of GEO-MVA Mpox/Smallpox VaccineYahoo Finance·Mar 11, 2026
- Siga Technologies Q4 Earnings Call HighlightsMarketbeat·Mar 10, 2026
- GeoVax Announces Oncology Advisory Board to Advance Gedeptin(R) Development Across Solid TumorsYahoo Finance·Feb 24, 2026
- Shopify, eBay upgraded: Wall Street's top analyst callsYahoo Finance·Feb 19, 2026
- GeoVax Secures Exclusive License for Gedeptin(R) + Immune Checkpoint Inhibitor Combination TechnologyYahoo Finance·Feb 18, 2026
- GeoVax Endorses Global Call to Sustain Mpox Response as Evidence Confirms Epidemic Is Far From OverYahoo Finance·Feb 17, 2026
- GeoVax Labs Announces $1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesYahoo Finance·Feb 13, 2026
- GeoVax Highlights 2026 as a Pivotal Year for ProgressYahoo Finance·Jan 20, 2026
All 21 articles loaded
Price Data
Open$1.44
Previous Close$1.42
Day High$2.00
Day Low$1.38
52 Week High$34.75
52 Week Low$0.96
52-Week Range
$0.96$34.75
$1.65
Fundamentals
Market Cap$5M
P/E Ratio—
EPS$-22.40
Dividend Yield—
Dividend / Share—
ROE-4.8%
Profit Margin—
Debt / Equity—
Trading
Volume1.4M
Avg Volume (10D)—
Shares Outstanding2.9M
About Geovax Labs Inc
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using a modified vaccinia ankara virus-like particle vaccine platform. The company is headquartered in Smyrna, Georgia.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—